New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
With the passage of H.R. 2055 last December, NIH effectively lowered the salary cap for principal investigators and officials by $20,000. Executive Level 2, which totals $179,700.00, is now in place of Executive Level I, which was $199,700.00. According to Jameson & Company, a CPA firm that works with government grantees and contractors, this development “will have a major effect on University NIH Grants, R01s, and SBIR/STTR and the direct salary received from these awards.” Do you think NIH scientists will leave that revered institution for the potential greener pastures in industry?